Results 11 to 20 of about 114,065 (338)

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
A Hochhaus, A Ptasznik, A Serrels, A Veldurthy, AC Shor, Alison M. McCaig, Alison M. Michie, AM McCaig, CD Allen, CM Pleiman, DY Hallaert, Emilio Cosimo, J Hoellenriegel, J Hoellenriegel, JA Burger, JA Burger, JA Burger, JW Friedberg, LJ Lombardo, M Buchner, M Burger, M Lopez-Guerra, M Niedermeier, M O'Hayre, MF de Rooij, Michael T. Leach, MP Quiroga, O Hantschel, P Ghia, PC Amrein, R Buettner, RE Hayden, S Braselmann, S Ponader, S Willimott, SJ Richardson, Spencer B. Gibson, Y Nakata, Z Song   +38 more
core   +8 more sources

Chronic lymphocytic leukaemia [PDF]

Clinical Medicine, 2001
Le tableau clinique, le diagnostic et les differents traitements de la leucemie lymphocytaire chronique sont ...
C, Singer, T, Goldstone
openaire   +2 more sources

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

British Journal of Haematology, 2022
Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and acquired resistance to BTKi can be seen due to a variety of mechanisms including ...
Shazia Nakhoda, A. Vistarop, Y. L. Wang
semanticscholar   +1 more source

Synchronous metastatic cutaneous squamous cell carcinoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma in a cervical lymph node: case report of an unusual event [PDF]

, 2015
The synchronous occurrence of two different neoplasias is an uncommon event, which may arise between tumors originating in the same organ or in cancer-to-cancer metastasis.
Altemani, Albina, Andrade, Bruno Augusto Benevenuto de, dos Santos, Harim Tavares, Filho, Edson Robles Castilla   +3 more
core   +4 more sources

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

Blood Cancer Journal, 2021
B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection.
Helen M Parry, G. McIlroy, R. Bruton, Myah Ali, Christine Stephens, S. Damery, A. Otter, T. McSkeane, Hayley Rolfe, S. Faustini, Nadezhda Wall, P. Hillmen, G. Pratt, S. Paneesha, J. Zuo, A. Richter, P. Moss   +16 more
semanticscholar   +1 more source

Growth dynamics in naturally progressing chronic lymphocytic leukaemia

Nature, 2019
M. Gruber, I. Bozic, I. Leshchiner, D. Livitz, K. Stevenson, L. Rassenti, D. Rosebrock, A. Taylor-Weiner, Oriol Olive, Reaha Goyetche, S. Fernandes, Jing Sun, C. Stewart, Alicia Wong, C. Cibulskis, Wandi Zhang, Johannes G. Reiter, Jeffrey M. Gerold, J. Gribben, K. Rai, M. Keating, Jennifer R. Brown, D. Neuberg, T. Kipps, M. Nowak, G. Getz, Catherine J. Wu   +26 more
semanticscholar   +3 more sources

Prolegomenon for Chronic Lymphocytic Leukaemia [PDF]

Scandinavian Journal of Immunology, 2003
AbstractChronic lymphocytic leukaemia (CLL) is a unique lymphoproliferative disorder that scarcely occurs under the age of 40; thereafter the incidence of CLL increases exponentially with age. CLL is characterized by progressive expansion of malignant CD5+ME+ B‐cell clone accompanied by a myriad of cellular and humoral immune defects.
Vitale, Branko, Martinis, Mladen, Antica, Mariastefania, Kušić, Borka, Rabatić, Sabina, Gagro, Alenka, Kušec, Rajko, Jakšić, Branimir   +7 more
openaire   +3 more sources

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

The Lancet Haematology, 2021
BACKGROUND We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable minimal residual disease (MRD),
J. Soumerai, A. Mato, A. Dogan, V. Seshan, E. Joffe, K. Flaherty, J. Carter, E. Hochberg, J. Barnes, A. Hamilton, J. Abramson, C. Batlevi, M. Matasar, A. Noy, C. Owens, M. Palomba, Anita Kumar, T. Takvorian, A. Ni, M. Choma, C. Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, L. Ramos, Natascha Nolet, Neena Mahajan, R. Martignetti, Joanna Mi, K. Scorsune, J. Lynch, B. McGree, S. Hughes, C. Grieve, L. Roeker, Meghan C. Thompson, P. Johnson, M. Roshal, Jane E. Huang, J. Biondo, Q. Wu, A. Jacob, O. Abdel-Wahab, A. Zelenetz   +45 more
semanticscholar   +1 more source

Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukemia

Haematologica, 2020
Retrotransposons such as LINE-1 and Alu comprise >25% of the human genome. While global hypomethylation of these elements has been widely reported in solid tumours, their epigenetic dysregulation is yet to be characterised in chronic lymphocytic ...
Timothy M. Barrow, Nicole Wong Doo, Roger L. Milne, Graham G. Giles, Elaine Willmore, Gordon Strathdee, Hyang-Min Byun   +6 more
doaj   +1 more source

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

The Lancet, 2020
BACKGROUND Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients ...
J. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, J. Pagel, I. Flinn, M. Kamdar, T. Munir, R. Walewska, G. Corbett, L. Fogliatto, Y. Herishanu, V. Banerji, S. Coutre, G. Follows, P. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, J. Woyach, G. Salles, W. Wierda, R. Izumi, V. Munugalavadla, P. Patel, M. Wang, S. Wong, J. Byrd   +28 more
semanticscholar   +1 more source